A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 188 participants.
Also called NCT03496623
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 188 participants
- Sponsor
- Registry
-
NCT03496623
-
- Other papers using this trial's data
- Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Israel, Puerto Rico
- Registry status
- Terminated
Technical summary
Registry record NCT03496623. Randomized; quadruple masking; primary purpose treatment. Start 2018-05-08 (actual); primary completion 2022-10-13 (actual). Results posted on 2023-11-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
- Acronym
- PERFECT
- Condition
- Pulmonary Hypertension
- Condition
- Chronic Obstructive Pulmonary Disease
- Intervention (Drug)
- Inhaled treprostinil solution
- Intervention (Drug)
- Placebo solution
- Lead sponsor
- United Therapeutics
Record details
- Record id
cardio:ct-nct03496623- Content hash
82f889d9249d0aae6e42851e796ba34f9e36fd7c3a90efa6aeef1fc6f55908b4